Results 11 to 20 of about 77,046 (263)

B-cell non-Hodgkin lymphomas [PDF]

The Lancet
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases.
Elisabeth, Silkenstedt, Gilles, Salles, Elias, Campo, Martin, Dreyling   +3 more
openaire   +3 more sources

Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma [PDF]

Discover Oncology
Background The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an immunomodulatory drug that has shown promising properties and activity in a variety of hematological ...
Yang Liu, Yanju Li, Chike Zhang, Xu Yang, Bo Yang, Jinyang Cheng, Juan Chen, Xiaoshuang Yuan, Ya Li, Ying Chen, Fengqi Zhang, Dongxin Tang, Zhixu He, Feiqing Wang   +13 more
doaj   +2 more sources

Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma [PDF]

Frontiers in Oncology, 2013
This manuscript reviews current advances in the use of radioimmunotherapy (RIT) for the treatment of B-cell non-Hodgkin's lymphoma (NHL). RIT has been in use for more than 20 years and has progressed significantly with the discovery of new molecular targets, the development of new stable chelates, the humanization of monoclonal antibodies (MAbs), and ...
Caroline eBodet-Milin, Ludovic eFerrer, Amandine ePallardy, Thomas eEugène, Aurore eRauscher, Alain eFaivre-Chauvet, Jacques eBarbet, Jacques eBarbet, Françoise eKraeber-Bodéré   +8 more
openaire   +3 more sources

Cytokine expression in B‐cell non‐Hodgkin lymphomas [PDF]

Hematological Oncology, 1990
AbstractCytokine expression of potentially active B‐cell growth factors (IL‐2, IL‐4, IL‐6) was investigated by means of mRNA‐expression in 29 cases of malignant non‐Hodgkin B‐cell lymphomas. Strong signals were found for IL‐4 and IL‐6 in two and five cases, respectively, whereas the majority of the remaining cases did not show any detectable mRNA ...
Merz, H., Fliedner, A., Lehrnbecher, T., Sebald, Walter, Müller-Hermelink, H. K., Feller, A. C.   +5 more
openaire   +3 more sources

Telomerase activity in B-cell non-Hodgkin lymphoma [PDF]

Cancer, 2000
Studies have shown telomerase activity to be present in some B-cell non-Hodgkin lymphomas (B-NHLs). However, no large studies have assayed telomerase activity in a systematic and quantitative manner. Furthermore, the relation between telomerase and proliferation suggested by in vitro studies has not been adequately tested in B-NHLs in vivo.
S A, Ely, A, Chadburn, C M, Dayton, E, Cesarman, D M, Knowles   +4 more
openaire   +2 more sources

The molecular pathogenesis of B‐cell non‐Hodgkin lymphoma [PDF]

European Journal of Haematology, 2015
AbstractThe B‐cell non‐Hodgkin lymphomas (B‐NHL) are a diverse group of haematological malignancies which arise from the mature B‐lymphocyte compartment. Recently, our understanding of the molecular pathogenesis of these disorders has greatly increased due to technological advances such as high‐throughput DNA sequencing techniques.
Piers A, Blombery, Meaghan, Wall, John F, Seymour   +2 more
openaire   +2 more sources

Radioimmunotherapy for B-Cell Non-Hodgkin Lymphomas [PDF]

Cancer Control, 2012
Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan and 131I-tositumomab) are available in the United States.
openaire   +2 more sources

Thymic B-cell non-Hodgkin's lymphoma in a child [PDF]

American Journal of Hematology, 1998
A 13-year-old male developed thymic non-Hodgkin's lymphoma. Microscopically, the tumor was composed of large cells, resembling centroblasts. Immunohistochemically, the tumor demonstrated leukocyte common antigen+, L26 (B-cell)+, UCHL1 (T-cell)-, suggesting the B-cell phenotype.
E, Azuma, H, Nishihara, J, Qi, M, Nagai, S, Hiratake, X L, Zhang, Y, Komada, M, Hamazaki, M, Sakurai   +8 more
openaire   +2 more sources

Genomic landscape of mature B-cell non-Hodgkin lymphomas — an appraisal from lymphomagenesis to drug resistance

Journal of the Egyptian National Cancer Institute, 2022
Background Mature B-cell non-Hodgkin lymphomas are one of the most common hematological malignancies with a divergent clinical presentation, phenotype, and course of disease regulated by underlying genetic mechanism.
Devasis Panda, Nupur Das, Deepshi Thakral, Ritu Gupta   +3 more
doaj   +1 more source

Primary T-Cell Non-Hodgkin Lymphoma of the Vagina

Case Reports in Obstetrics and Gynecology, 2015
The primary vaginal T-cell non-Hodgkin lymphoma is a rare form of lymphoma. Most of the previously published cases were about B-cell non-Hodgkin lymphomas. We present the case of a vaginal mass in an 82-year-old patient presenting vaginal bleeding.
J. L. Herraiz, A. Llueca, Y. Maazouzi, D. Piquer, A. Palmeiro, E. Calpe   +5 more
doaj   +1 more source